Pylarify drug

Ended Awarded Last action

Contract number
36C25523A0018
Awardee
Awarding agency
Task orders
2 $996,007 obligated

Award facts

Combined order value
$996,007 Current and potential, with all options
Last date to order 100% complete
IDV ceiling 84% used
$1,188,615.44
Maximum order
$999,615.44
Award type
Single award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The key products and services being delivered under this Blanket Purchase Agreement (BPA) federal contract Indefinite Delivery Vehicle (IDV) are PYLARIFY (piflufolastat F-18), a radiopharmaceutical drug used for positron emission tomography (PET) imaging of prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and a subsidiary of Lantheus Holdings, Inc. The contract, valued at up to $1,188,615.44, was awarded by the U.S. Department of Veterans Affairs (VA) and the Defense Health Agency (DHA), with the VA as the primary customer procuring PYLARIFY for use in its medical facilities across the Veterans Integrated Service Network (VISN) 15 region. The contract is not set aside for any specific business type and is associated with the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The period of performance extends to May 31, 2024, with task orders ranging from small quantities for specific facilities to larger, network-wide orders to ensure a steady supply of this critical diagnostic agent for federal healthcare programs.

Progenics Pharmaceuticals, a pharmaceutical company specializing in innovative medicines and artificial intelligence solutions for the diagnosis and treatment of cancer and other diseases, has received multiple federal contract awards from agencies such as the VA, DHA, and National Institutes of Health to provide radiopharmaceuticals, radioactive diagnostic agents, and prostate cancer medications. The PYLARIFY drug is Progenics' flagship product, and these federal contracts, typically awarded as firm fixed price delivery orders or purchase orders, facilitate the ongoing procurement of PYLARIFY and other radiopharmaceuticals for cancer detection and treatment by various government healthcare providers.

Task orders

Task order Ordering agency Obligated Awarded
Pylarify drug 36C25524N0212 Veterans Integrated Service Network 15 (VHA) $230,958
Pylarify drug 36C25523N0196 Veterans Integrated Service Network 15 (VHA) $765,049

Transactions

Action Obligated Date
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 36C25523A0018?

36C25523A0018 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 15 (Veterans Health Administration) on March 1, 2023.

How much is contract 36C25523A0018 worth?

Orders under 36C25523A0018 have obligated $996,007. 36C25523A0018's own ceiling is $1,188,615. A single order can be worth up to $999,615.

How many orders have been placed under contract 36C25523A0018?

2 orders have been placed under 36C25523A0018, the latest on March 1, 2024.

Who can order from contract 36C25523A0018?

36C25523A0018 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

Is contract 36C25523A0018 under another contract?

Yes. 36C25523A0018 is a blanket purchase agreement under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36C25523A0018 competed?

The extent of competition for 36C25523A0018 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV